Candel Therapeutics (CADL) Capital Expenditures (2020 - 2025)
Candel Therapeutics (CADL) reported Capital Expenditures of -$46000.0 for Q4 2025, down 1633.33% on a YoY basis from $3000.0 in Q4 2024, and down 131.94% sequentially from $144000.0 in Q3 2025.
Candel Therapeutics (CADL) Capital Expenditures (2020 - 2025) Analysis & Trends
Candel Therapeutics (CADL) has 6 years of Capital Expenditures data on file, last reported at -$46000.0 in Q4 2025.
- For the quarter ending Q4 2025, Capital Expenditures fell 1633.33% year-over-year to -$46000.0; the trailing twelve-month figure through Dec 2025 stood at $132000.0 (up 725.0% YoY), and the FY2025 full-year result was $132000.0, up 725.0% from the prior year.
- Capital Expenditures fell to -$46000.0 in Q4 2025, from $144000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $1.8 million in Q1 2021 to a low of -$1.4 million in Q4 2021.
- A 5-year average of $31105.3 and a median of $6000.0 in 2024 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures sank 10200.0% in 2021 and soared 372.95% in 2022, its largest moves.
- Tracing CADL's Capital Expenditures over 5 years: stood at -$1.4 million in 2021, then jumped by 32.67% to -$952000.0 in 2022, then soared by 146.01% to $438000.0 in 2023, then plunged by 99.32% to $3000.0 in 2024, then plunged by 1633.33% to -$46000.0 in 2025.
- Business Quant data shows CADL's Capital Expenditures at -$46000.0 in Q4 2025, $144000.0 in Q3 2025, and $18000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 43.25 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 786,000.00 |
| 10 | Candel Therapeutics | 504.70 Mn | 504.70 Mn | - | -46,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -46,000.00 |
| Dec 31, 2025 | -46,000.00 |
| Sep 30, 2025 | 144,000.00 |
| Sep 30, 2025 | 144,000.00 |
| Jun 30, 2025 | 18,000.00 |
| Jun 30, 2025 | 18,000.00 |
| Mar 31, 2025 | 16,000.00 |
| Mar 31, 2025 | 16,000.00 |
| Dec 31, 2024 | 3,000.00 |
| Dec 31, 2024 | 3,000.00 |
| Jun 30, 2024 | 6,000.00 |
| Jun 30, 2024 | 6,000.00 |
| Mar 31, 2024 | 7,000.00 |
| Mar 31, 2024 | 7,000.00 |
| Dec 31, 2023 | 438,000.00 |
| Dec 31, 2023 | 438,000.00 |
| Sep 30, 2023 | 3,000.00 |
| Sep 30, 2023 | 3,000.00 |
| Jun 30, 2023 | -122,000.00 |
| Jun 30, 2023 | -122,000.00 |